Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6

We developed a therapeutic, gene-modified, allogeneic melanoma vaccine (AGI-101H), which, upon genetic modification, acquired melanoma stem cell-like phenotype. Since its initial clinical trial in 1997, the vaccine has resulted in the long-term survival of a substantial fraction of immunized patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Czerwinska, Patrycja, Rucinski, Marcin, Wlodarczyk, Nikola, Jaworska, Anna, Grzadzielewska, Iga, Gryska, Katarzyna, Galus, Lukasz, Mackiewicz, Jacek, Mackiewicz, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959432/
https://www.ncbi.nlm.nih.gov/pubmed/32002306
http://dx.doi.org/10.1080/2162402X.2019.1710063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959432/
https://www.ncbi.nlm.nih.gov/pubmed/32002306
http://dx.doi.org/10.1080/2162402X.2019.1710063

Ejemplares similares